PCRX
Pacira BioSciences, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$36.39
+0.00%Oct 8, 2026, 21:52 UTC
Brodsky & Smith announced an investigation into potential claims against Pacira BioSciences' board concerning its proposed sale to Viatris.
Source:Oct 8, 2026, 12:19 UTC
Pacira BioSciences, Inc. shares surged 44.3% in premarket trading.
Source:Oct 8, 2026, 11:45 UTC
Viatris Inc agreed to acquire all outstanding shares of Pacira BioSciences, Inc. for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion.
Oct 7, 2026, 12:00 UTC
Pacira BioSciences and Caregiver Action Network announced findings from the Ready, Set, Recover initiative on family caregivers’ experiences preparing for surgery and managing postsurgical recovery at home.
Source:Oct 5, 2026, 12:00 UTC
Pacira BioSciences announced an exclusive agreement with Molteni Farmaceutici to commercialize EXPAREL in the European Union and the United Kingdom.
Source:Aug 4, 2026, 20:01 UTC
Pacira BioSciences reported second quarter 2026 total revenue of $192.4 million, a 6 percent year-over-year increase, and highlighted continued execution of its 5x30 strategy with solid revenue growth, durable cashflows, advancing pipeline, and commercial partnerships.
Jul 1, 2026, 12:00 UTC
UnitedHealthcare now provides separate reimbursement for Pacira BioSciences' EXPAREL across outpatient settings.
Source:Jun 30, 2026, 00:00 UTC
Pacira BioSciences agreed to divest its Pacira CryoTech subsidiary and related cryoanalgesia device assets to Zimmer, Inc. for up to $140 million.
Source: